Apoptosis in neural development and disease

Nicholas D Mazarakis, A David Edwards, Huseyin Mehmet

Introduction
Neural cell death has a pivotal role in both the development and pathophysiology of the nervous system. Two distinct modes of cell death—necrosis and apoptosis—are involved in pathological neuronal loss, but apoptosis alone is the mechanism of programmed cell death during development. All cells will undergo apoptosis in the absence of survival signals, usually peptide growth factors secreted by other cells. This provides an elegant mechanism for the control of neuronal development: a surplus of neurons is produced, and only those that form the correct connections with the target tissue receive adequate survival factors. The remainder undergo apoptotic death and removal. Apoptosis continues throughout life and is the central mechanism for the removal of surplus, unwanted, damaged or aged cells. Dysregulation of apoptosis is seen after cellular insults or in neurodegeneration as well as in tumourigenesis. Strategies which influence the apoptotic pathway offer valuable therapeutic approaches in a variety of pathological states.

Apoptosis
The term programmed cell death was first used by Lockshin and Williams in 1964, to describe the pre-determined loss of specific cells during insect metamorphosis by an intrinsic cellular suicide programme.\(^1\) In a seminal paper Kerr, Wyllie, and Currie\(^1\) later coined the word apoptosis to describe this form of death and went on to show that it was a widespread process in nature, occurring both during normal physiological development and in many pathological conditions.

Apoptosis is a well conserved and highly regulated mechanism of cell death for the removal of unnecessary, surplus, aged or damaged cells. Dysregulation of apoptosis can result in the persistence of mutated cells, leading to malformations, autoimmune disease, and cancer. On the other hand, inappropriate apoptosis resulting in the removal of healthy cells can occur in diseases such as infection, hypoxic–ischaemic injury, neurodegenerative or neuromuscular diseases, and AIDS.

Apoptosis can be distinguished from necrotic cell death\(^2\): in necrosis, a cell’s demise is precipitated by an external insult and involves the early loss of membrane integrity, with damage to organelles and the leakage of cytoplasmic contents, leading to the recruitment of phagocytes with an acute inflammatory reaction. In contrast, apoptosis is cellular suicide. Cells dying by apoptosis retain membrane and organelle function until late in the process, while developing plasma membrane blebbing, reduced cytoplasmic volume, chromatin condensation and nuclear fragmentation. In the final stages cellular fragments wrapped in plasma membrane bud off as apoptotic bodies which are subsequently phagocytosed by healthy neighbouring cells.\(^3\) The elimination of cell debris occurs in the absence of an inflammatory response, and this quiet, rapid, and efficient removal of apoptotic cells means that apoptosis can be difficult to detect in tissue: although as many as 50% of the cells in a developing organ may undergo apoptosis, less than 1% of cells are apoptotic at any one time.

Apoptosis in the developing nervous system
Programmed cell death by apoptosis occurs in many developmental processes, including body sculpting (such as digit formation), elimination of self-reacting immune cells, sexual organ development and gamete formation.\(^3\) Indeed, a general principle of development in multicellular organisms is emerging: excess numbers of cells are made, and then surplus or unwanted cells are removed by apoptosis during the formation of functional organs.

In the developing nervous system apoptosis is observed as early as neural tube formation and persists throughout terminal differentiation of the neural network. The emergence of the neurotrophic hypothesis from the pioneering work of Levi-Montalcini, Hamburger, and Cohen\(^4\) established that more than 50% of neurons are lost during development as a result of limiting trophic support from the target tissue they are destined to innervate. This neuronal attrition, which ensures appropriate connections in the central and peripheral nervous systems, was subsequently shown to be effected by the induction of apoptosis in unwanted cells.

A growing number of neurotrophic factors, such as the nerve growth factor family, the neurokines, and growth factors such as insulin-like growth factors (IGF-I and IGF-II) support the survival of particular types of neurons.\(^7,10\) Targeted disruption of genes encoding these factors or their receptors indicates that particular neurotrophic factors are important for the development of specific neuronal populations.\(^11\)

Neurotrophic factors function by binding to specific receptors in the cell membrane, and the effects of NGF offer an example of the subtle control that the system allows. The nerve growth factor receptor has high and low affinity components. It will function as a survival factor if it binds to the high affinity trkA receptor, but will induce apoptosis of retinal neurones\(^12\) or oligodendrocytes\(^13\) when it binds to the low affinity receptor p75 in the...
Apoptosis can be initiated by diverse signals, including the withdrawal of survival signals, exposure to pro-apoptotic stimuli such as DNA damage, reduced intracellular ATP concentrations, or binding of ligands to specific receptors in the plasma membrane. Several such “death” receptors have been defined, including p75, Fas/APO-1, and the tumour necrosis factor (TNF) receptor. Signal transduction from these receptors is mediated through a growing family of adaptor molecules that either directly or indirectly activate the enzymes that begin the dismantling of cell proteins and nucleic acids. In the case of Fas/APO-1, ligand binding induces receptor oligomerisation and subsequent binding of the Fas associating death domain protein, FADD. This molecule in turn recruits FLICE (FADD-like ICE), a member of the caspase family of proteases involved in orchestrating the apoptotic programme.

After the initiation of the apoptotic programme commitment to apoptosis is not immediate. The time at which a cell becomes irreversibly committed to death can vary from a few minutes to several hours or longer. The decision to commit is affected by a delicate balance between pro- and anti-apoptotic forces within the cell. Many of the participants in the apoptotic cascade have opposing partners, so that the decision to live or die depends on whether pro- or anti-apoptotic signals are dominant. A growing number of second messengers have also been implicated in regulating the apoptotic process. These include protein kinase C, cyclic AMP, calcium, and ceramide. Until commitment is made, the outcome can be influenced by manipulation of these forces, and the process is subject to regulation. However, commitment marks a point of no return when anti-apoptotic intervention ceases to be effective.

The opposing aspects of cell survival and death are illustrated by the bcl-2 family of proteins. These genes are homologous to the anti-apoptotic gene, ced-9, identified in the nematode C elegans as an upstream inhibitor of the pro-apoptotic genes ced-3 and ced-4. In mammalian cells the bcl-2 family includes both anti-apoptotic proteins, such as bcl-x and bcl-2 itself, and their pro-apoptotic partners, including bax and bad. Bcl-2 family members can form heterodimers with each other and it is the antagonistic balance between bcl-2/bcl-x and bax/bad which controls the cellular decision to live or commit suicide. Bcl-2 was originally identified in chromosomal translocations in follicular lymphoma, and this family of proteins also has a role in neuronal apoptosis. Although bcl-2 deletion in transgenic mice is not lethal and has no neuronal phenotype at birth, substantial degeneration of motor, sensory, and sympathetic neurons occurs after the physiological cell death period. This suggests that bcl-2 is not a neurodevelopmental survival signal but is crucial for the maintenance of specific populations of neurons during the early postnatal period. In accordance with this, bcl-2...
Apoptosis in neural development and disease

F167

Caspases.33 The caspases thus constitute an amplification mechanism for apoptotic signals. They are activated soon after the death trigger and cleave specific cellular targets, such as the DNA repair enzyme poly-ADP-ribose polymerase, presumably in preparation for ultimate cellular degradation. The importance of these enzymes in neuronal survival is illustrated by transgenic experiments where overexpression of a dominant negative caspase protects mice from cerebral ischaemia.34

Recent work has emphasised the role of mitochondria in the regulation of apoptosis.35 Bcl-2 family genes and ced-4 are located on the outer mitochondrial membrane, and genetic deletion of the membrane binding domains from the protein sequence attenuates their function. The release of cytochrome-c from mitochondria is required for execution to proceed in some cell lines, and mitochondria in apoptotic cells also release a pro-apoptotic peptide, apoptosis inducing factor. It has thus been suggested that the mitochondrion is the central control point of apoptotic execution, and that the opening of channels in the inner mitochondrial membrane, to cause the mitochondrial membrane permeability transition, is the final common pathway to apoptotic death. This hypothesis has several points in its favour, not least in offering an explanation of how cellular insults such as hypoxia–ischaemia can cause both apoptosis and necrosis.

In the late stages of apoptotic execution the organised degradation of genomic DNA is carried out by unidentified endonucleases. The activation of these enzymes is concurrent with, or immediately consequent on, caspase activation, although the precise mechanisms are as yet unknown. The end result of endonuclease activation is the internucleosomal cleavage of DNA, first leading to high molecular weight fragments (50 to 300 kb), and eventually to characteristic DNA “ladders” that can be detected by gel electrophoresis.30

Methods for detecting apoptosis

As both apoptosis and necrosis can occur simultaneously, it has become increasingly important to distinguish between these two modes of cell death. Differences can be observed by light or electron microscopy, and no other method for distinguishing apoptosis from necrosis has been shown to be as reliable as morphological analysis using appropriate stains. However, a variety of methods are in use, including: fluorescence activated cell sorting; detection of DNA fragmentation, either by agarose gel electrophoresis which demonstrates characteristic “ladders”; or the terminal deoxynucleotidyl transferase mediated biotin dUTP nick end-labelling (TUNEL) and in situ end labelling (ISEL) techniques which use DNA polymerase to repair DNA nicks with labelled nucleotides.39

Apoptosis in nervous system injury and disease

Although apoptosis is involved in a number of diseases of the nervous system, in most cases the link between a specific mutation or injury and the activation of apoptotic cascades remains elusive. A summary of a growing list of neurological diseases in which apoptosis has been implicated as an important pathological mechanism is given below.

NEURONAL INJURY

Cerebral hypoxic–ischaemic injury is a significant cause of death and neurological impairment. Magnetic resonance spectroscopy studies have shown that transient hypoxia–ischaemia leads to a biphasic disruption of cerebral energy metabolism. Related to this biphasic energy failure, two waves of cell death seem to follow hypoxic–ischaemic injury in the developing brain. Immediate neuronal death is probably largely due to necrosis, resulting mainly from the accumulation of calcium ions, leading to membrane pump failure.40 Delayed cell death resulting from hypoxic–ischaemic injury seems to involve different or additional mechanisms and a growing body of data suggests that in the delayed phase of injury cell death occurs by apoptosis.41 The amount of apoptosis is directly related to the magnitude of ATP depletion during hypoxia–ischaemia.42 43 Significant amounts of apoptosis have been observed in the brains of newborn infants following both birth asphyxia and sudden intrauterine death44 and apoptosis is also prominent in white matter injury in newborn infants. There is evidence that apoptosis may continue for many weeks after an hypoxic–ischaemic insult,45 and this may be related to the persistent changes in cerebral energy metabolism seen in infants during the months following birth asphyxia.46

Following focal neural injury, apoptosis has been detected in sites distant from the initial damage. After acute spinal cord injury in monkeys apoptosis of oligodendrocytes occurs in remote degenerating fibre tracts,47 and after forebrain injury in developing rats apoptosis can be observed in the cerebellum.48 The apoptotic loss of oligodendrocytes could thus be a possible cause of secondary demyelination in paraplegia and in the chronic degeneration associated with multiple sclerosis. Further evidence for a role for apoptosis in this type of injury comes from the report that bcl-2 expression promotes the growth and regeneration of retinal axons.49

Downloaded from http://fn.bmj.com/ on June 19, 2017 - Published by group.bmj.com
NEURAL CANCERS
An intimate connection between apoptosis and the cell cycle has been shown in carcinogenesis: proto-oncogenes such as c-fos, c-jun, and c-myc can trigger apoptosis and promote cell division, while inactivation of the pro-apoptotic p53 tumour suppressor gene is a frequent marker of human neoplasia. For example, in a number of gliomas the loss of wild p53 activity has been linked to tumour progression, possibly resulting in resistance to chemotherapy and radiotherapy. Although there have been reports of bcl-2 overexpression in glioma cell lines, the correlation between the anti-apoptotic effect of this gene and malignancy is not clear. However, a homologue of bcl-2, the brain related apoptosis gene (BRAG-1), is found predominantly in the brain, and is upregulated in human gliomas as a rearranged transcript.

INFECTIOUS DISEASE
Apoptosis may have a role in HIV encephalopathy. In the brain the virus replicates primarily in microglia which it enters via the CD4 receptor. Although the activation of microglia is thought to be the primary cause of neuronal loss and demyelination, neurons die by apoptosis in HIV encephalopathies perhaps due to loss and demyelination, neurons die by apoptosis. The general importance of apoptosis in HIV mediated alteration in astrocyte function and aberrant stimulation of NMDA receptors, or by the accumulation of nitric oxide following the activation of inducible nitric oxide synthase.

In subacute sclerosing panencephalitis widespread apoptotic death has been detected in the brain, although no correlation was observed between viral load, lymphocyte infiltration, and the number of apoptotic cells. DNA fragmentation indicative of apoptosis has been detected in scrapie infected sheep and mouse brain, suggesting a role for this mode of cell death in spongiform encephalopathies.

NEURODEGENERATION
Spinal muscular atrophy is associated with mutations in the survival of motor neuron and neuronal apoptosis inhibitory protein (NAIP) genes. NAIP is related to the baculovirus inhibitor of apoptosis protein and inhibits apoptosis in several cell types. This implies that mutations in NAIP could deregulate apoptosis in spinal motor neurons, thus causing their death. The general importance of anti-apoptotic genes in neuronal protection is emphasised by recent reports that NAIP overexpression can also rescue neurons after cerebral ischaemia.

Apoptosis has also been implicated in retinal dystrophies such as retinitis pigmentosa. In this instance, apoptosis results from mutations in any one of the three photoreceptor genes rhodopsin, peripherin, and the β-subunit of cyclic guanosine monophosphate diesterase, resulting in photoreceptor degeneration. Although the apoptotic trigger is unknown, absence of c-fos prevents apoptosis in these cells. Moreover, defined neurotrophins and growth factors injected intraocularly in animal models of retinal degeneration enhance photoreceptor survival, implying that the apoptotic cascade can be blocked by supplying exogenous survival signals.

The mutation underlying Huntington’s disease is an expanded trinucleotide repeat within a novel gene, huntingtin, that is crucial for normal development and can be regarded as a cell survival gene. Transgenic models null for the huntingtin gene show increased apoptosis in neurons of the embryonic neuroectoderm. Moreover, huntingtin is specifically cleaved during apoptosis by caspase-3 (apopain) and the rate of cleavage is enhanced by a gain of function associated with the triplet expansion. This is also supported by the observation that overexpression of the specific trinucleotide repeats in transgenic mice is sufficient to induce the Huntington’s phenotype.

Most cerebellar ataxias are associated with neuronal loss. Ataxia telangectasia, caused by mutations in the ATM gene, is thought to have an apoptotic component. ATM shares extensive and important homology with the DNA dependent protein kinases involved in DNA damage responses at different cell cycle check points, and is downregulated in all patients with ataxia telangectasia. The fact that inappropriate p53 mediated apoptosis is the major cause of death in ataxia telangectasia cells irradiated in vitro suggests that the mutation causes inappropriate triggering of apoptosis by otherwise non-lethal DNA damage.

In the familial form of amyotrophic lateral sclerosis gain of function mutations in the gene encoding copper zinc superoxide dismutase (sod-1) create a dominant pro-apoptotic signal. Although cell injury by accumulation of free radicals can trigger apoptosis, these mutants can induce apoptosis both in neural cells in culture and in transgenic mice.

Mental retardation in Down’s syndrome has also been linked to inappropriate apoptosis. Although cortical neurons from fetal Down’s syndrome brains differentiate normally in culture, they subsequently degenerate and undergo apoptosis. Degeneration is blocked by treatment with free radical scavengers, suggesting that a defect in metabolism of reactive oxygen species is the trigger for apoptosis.

In Parkinson’s disease the death of dopaminergic neurons in the substantia nigra has been shown to occur by apoptosis and can be blocked by delivery of glial derived neurotrophic factor. Alzheimer’s disease is associated with the progressive accumulation of β-amyloid protein which is the major component of neural plaques. The β-amyloid peptide can induce neurons to undergo apoptosis in vitro.

INHERITED METABOLIC DISEASES
There are some data to suggest that the acute encephalopathy associated with maple syrup urine disease is due to the induction of apoptosis by an accumulating metabolite of leucine, α-keto isocaproic acid. This compound is a potent inducer of apoptosis in central nervous system glial cells in culture, and the effect is enhanced in the presence of leucine. Phenylalanine and leucine alone do not induce
apoptosis in this system, suggesting that this effect is specific (unpublished observations).

**Therapeutic manipulation of the apoptotic programme**

**INHIBITION OF APOPTOSIS**

As apoptosis is a highly regulated physiological process, a window of opportunity exists for therapeutic intervention. However, if anti-apoptotic strategies are to be successful, first it must be established that apoptosis is a major component leading to the neuronal defect, second that inhibition of cell death does not result in the persistence of damaged neurons, and third, that the anti-apoptotic treatment can be applied before the cellular commitment to apoptosis.

Several anti-apoptotic agents reduce neuronal loss following cerebral ischaemia. Both IGF-1 and the protein synthesis inhibitor cycloheximide reduce cerebral injury if administered soon after hypoxia–ischaemia.78-79 Our own studies demonstrate that the administration of IGF-1 immediately after cerebral hypoxia–ischaemia reduces infarct volume resulting from focal ischaemia in rats.79 Our own studies with cycloheximide reveal a similar protective effect if administered immediately after cerebral hypoxia–ischaemia78 . Schlichter and colleagues79 have reported that the protein synthesis inhibitor cycloheximide reduces cerebral injury if administered immediately after cerebral hypoxia–ischaemia. In this respect, targeted delivery of normal alleles to replace mutated genes involved in neuronal degeneration, such as those encoding the Bcl-2 family proteins, is a long-term goal of gene therapy.80

**INDUCTION OF APOPTOSIS**

**INHIBITION OF APOPTOSIS**

As apoptosis is a highly regulated physiological process, a window of opportunity exists for therapeutic intervention. However, if anti-apoptotic strategies are to be successful, first it must be established that apoptosis is a major component leading to the neuronal defect, second that inhibition of cell death does not result in the persistence of damaged neurons, and third, that the anti-apoptotic treatment can be applied before the cellular commitment to apoptosis.

Several anti-apoptotic agents reduce neuronal loss following cerebral ischaemia. Both IGF-1 and the protein synthesis inhibitor cycloheximide reduce cerebral injury if administered soon after hypoxia–ischaemia.78-79 Our own studies demonstrate that the administration of IGF-1 immediately after cerebral hypoxia–ischaemia reduces infarct volume resulting from focal ischaemia in rats.79 Our own studies with cycloheximide reveal a similar protective effect if administered immediately after cerebral hypoxia–ischaemia. In this respect, targeted delivery of normal alleles to replace mutated genes involved in neuronal degeneration, such as those encoding the Bcl-2 family proteins, is a long-term goal of gene therapy.80

**INDUCTION OF APOPTOSIS**

The anti-tumour effect of radiotherapy and chemotherapy is effected through the induction of apoptosis in tumour cells. However, the considerable side effects of these pro-apoptotic treatments have led to the search for novel methods for promoting tumour apoptosis. Brain tumours have been treated successfully using the herpes thymidine kinase-gancyclovir gene therapy approach which works by target-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-


73 Olson L. The coming of age of the GDNF family and its receptors: gene delivery in a rat Parkinson model may have clinical implications. Trends Neurosci 1997;20:277-84.


Apoptosis in neural development and disease

Nicholas D Mazarakis, A David Edwards and Huseyin Mehmet

Arch Dis Child Fetal Neonatal Ed 1997 77: F165-F170
doi: 10.1136/fn.77.3.F165

Updated information and services can be found at:
http://fn.bmj.com/content/77/3/F165

These include:

References
This article cites 74 articles, 13 of which you can access for free at:
http://fn.bmj.com/content/77/3/F165#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the
box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Suicide (psychiatry) (6)
- Suicide (public health) (6)
- Drugs: CNS (not psychiatric) (191)
- Neuromuscular disease (9)
- Drugs: endocrine system (81)
- Immunology (including allergy) (393)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/